The predominant route of HIV transmission occurs across mucosal tissues. The earliest events that occur at the sites of transmission are poorly understood, yet an understanding of these events may provide critically important information that can be utilized in the development of an effective HIV vaccine. Multiple lines of investigation reveal that transmission of HIV across mucosal surfaces is inefficient. The virus must overcome multiple structural barriers and ultimately infect metabolically active CD4+ T cells. The process of infection requires that the HIV envelope protein first binds to the CD4 receptor and subsequently to a co-receptor, either CCR5 or CXCR4. However, the CD4 receptor is expressed at high levels not just on metabolically activated cells, but also on resting cells, which are a poor substrate for productive infection. We have identified the integrin alpha4-beta7 as an additional HIV receptor on the surface of CD4+ T cells. Unlike the CD4 receptor, integrin alpha4-beta7 is expressed on a subset of cells in mucosal tissues that tend to be metabolically activated. We hypothesize that the direct interaction between HIV gp120 and alpha4-beta7 provides two advantages to HIV that allow it to transmit across mucosal surfaces in a more efficient manner. By engaging alpha4-beta7 on a susceptible cell, a virion is able to target an important subset of CD4+ T cells that is highly susceptible to infection. In addition, alpha4-beta7+ CD4+ T cells migrate from genital mucosa into gut lymphoid tissues where an optimal cellular environment exists for viral replication. In this way, the specific affinity of the HIV envelope for alpha4-beta7 provides a plausible mechanistic explanation for the preferential establishment and/or maintenance of HIV replication in GALT. Understanding the specific molecular events surrounding mucosal transmission will hopefully allow us to identify new strategies to prevent HIV transmission.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Zip Code
Arrode-Brusés, Géraldine; Goode, Diana; Kleinbeck, Kyle et al. (2016) A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3. PLoS Pathog 12:e1005720
Cicala, Claudia; Nawaz, Fatima; Jelicic, Katija et al. (2016) HIV-1 gp120: A Target for Therapeutics and Vaccine Design. Curr Drug Targets 17:122-35
Kwon, Young Do; Pancera, Marie; Acharya, Priyamvada et al. (2015) Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 22:522-31
Park, Chung; Arthos, James; Cicala, Claudia et al. (2015) The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1(+) lymph node macrophages. Elife 4:
Hait, Sabrina H; Soares, Esmeralda A; Sprinz, Eduardo et al. (2015) Worldwide Genetic Features of HIV-1 Env α4β7 Binding Motif: The Local Dissemination Impact of the LDI Tripeptide. J Acquir Immune Defic Syndr 70:463-71
Joag, V R; McKinnon, L R; Liu, J et al. (2015) Identification of preferential CD4(+) T-cell targets for HIV infection in the cervix. Mucosal Immunol :
Byrareddy, Siddappa N; Sidell, Neil; Arthos, James et al. (2015) Species-specific differences in the expression and regulation of α4β7 integrin in various nonhuman primates. J Immunol 194:5968-79
Cicala, Claudia; Arthos, James (2014) Virion attachment and entry: HIV gp120 Env biotinylation, gp120 Env, or integrin ligand-binding assay. Methods Mol Biol 1087:3-12
Cimbro, Raffaello; Gallant, Thomas R; Dolan, Michael A et al. (2014) Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Proc Natl Acad Sci U S A 111:3152-7
Byrareddy, Siddappa N; Kallam, Brianne; Arthos, James et al. (2014) Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med 20:1397-400

Showing the most recent 10 out of 25 publications